Authors
Latest:
Future Perspectives and Unmet Needs in CLLThe panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
Latest:
COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best PracticesPanelists discuss how proactive management of adverse effects through the COCOON protocol represents a paradigm shift that could be applied to other EGFR inhibitors, emphasizing early intervention before symptoms appear.
Latest:
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and NeckThis study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.
Latest:
Pelabresib in MPNs: Immune Profiles of Responders vs. Non-respondersPanelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).
Latest:
Navigating AE Management for Cellular Therapy Across Hematologic CancersA panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Latest:
Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOLAuthors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.
Latest:
Unmet Needs and Future Directions for GPRC5D Bispecific TherapyPanelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
Latest:
Future Directions and Collaborations in Multiple MyelomaPanelists discuss how future directions in multiple myeloma include exciting developments like bispecific T-cell engagers (BiTEs) targeting B-cell maturation antigen (BCMA) and GPRC5D, dual-target chimeric antigen receptor (CAR) T therapies, and revolutionary in vivo CAR T approaches, while emphasizing the importance of nurse education and advocacy, compassionate patient-centered care, and a collaborative community approach where academic centers support community oncologists through accessible communication and shared care, ultimately working toward the goal of curing more patients, as evidenced by one-third of ciltacabtagene autoleucel (cilta-cel) recipients remaining in remission 5 years later without additional therapy.
Latest:
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and NeckThis study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple MyelomaCancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.
Latest:
Determining Suitable Radioligand Therapy Use in Neuroendocrine TumorsOncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.
Latest:
Metastatic CSPC: Future Directions in CareBefore closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
Latest:
Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung CancerOriginal research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.
Latest:
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLCThe expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Evaluation and Management of Testicular Cancer After Late RelapseThe clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Emerging Data and Future Directions in UCExperts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.
Latest:
Expert Commentary on the Product Profile of TepotinibIn an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
